Vical Inc., of San Diego, said an article in the journal Vaccine detailed results from the company's completed guinea pig studies with Vaxfectin-formulated plasmid DNA vaccines against herpes simplex virus type 2

The findings were presented at the 15th International Symposium on Anti-Angiogenic Therapy in San Diego

2012 U.S. Biotech Cluster Ranking 1 Greater Boston (no change) 2 San Diego (+5) 3 San Francisco Bay Area (no change) 4 Raleigh-Durham (+5) 5 Philadelphia (+1) 6 Washington D.C. Metro Area (-1) 7 New Jersey / New York City (-5) 8 Los Angeles / Orange County (-4) 9 Minneapolis-St. Paul (-1) 10 Seattle (no change) Source: Jones Lang LaSalle

In California, San Diego has risen from being the seventh to the second most-active U.S...San Diego recorded $13.8 billion in M&A activity in the last 12 months

Findings were presented at the GTCBIO Immune Responses in the Tumor Microenvironment Workshop in San Diego

Adventrx Pharmaceuticals Inc., of San Diego, said it started patient recruitment in its pivotal Phase III study of ANX-188 (purified poloxamer 188) in sickle cell disease

Auxilium Pharmaceuticals Inc., of Malvern, Pa., and Xstelos Holdings Inc., of New York, filed a lawsuit against Upsher-Smith Laboratories Inc., of San Diego, alleging infringement of 10 patents related to Testim 1 percent testosterone gel

La Jolla Pharmaceutical Co., of San Diego, said it administered the first dose for its Phase I/II trial of GCS-100 in patients with chronic kidney disease (CKD

Postmarketing work under way by way of EXAMINE help prove single-agent alogliptin's CVO-related safety, but the FDA approval helped by interim results could bode well for Orexigen Therapeutics Inc.'s FDA-stalled obesity therapy Contrave (naltrexone SR/bupropion SR), hit with a CRL in 2011 because of cardiovascular concerns. (See BioWorld Today, Feb. 2, 2011.) The FDA has told San Diego-based Orexigen and Takeda that interim data from their CVO trial – data that will be gathered after 87 major

coming, hopefully in the next week or two," said Jay Lichter, president and CEO of San Diego-based Afraxis, and managing partner with Avalon

In June, NovaRx Corp., of San Diego, completed enrollment in its Phase III trial testing Lucanix (belagenpumatucel-L), a whole tumor cell vaccine, in post-front-line maintenance in NSCLC

Location, Location, Location Researchers from the University of California at San Diego have shown that administering digestive enzyme blockers directly into the intestine improved the long-term survival of animals after shock

Trius Therapeutics Inc.'s president and CEO, Jeff Stein, told BioWorld Today last week his firm, which priced a $30 million offering, opted to raise money ahead of the impending debt ceiling crisis. (See BioWorld Today, Jan. 22, 2013.) By raising money now, San Diego-based Trius ensured it had sufficient capital to get its late-stage antibiotic tedizolid across the finish line

Epic Sciences Inc., of San Diego, received a Phase II SBIR award from the National Cancer Institute and National Institutes of Health to identify and characterize circulating tumor cells in lung cancer patients

Trius Therapeutics Inc., of San Diego, said underwriters in its recent public offering exercised their option to purchase an additional 869,135 shares, bringing the total number of shares in the offering to about 7.2 million, all sold at a price of $4.75 per share

Santarus Inc., of San Diego, and VeroScience LLC, of Tiverton, R.I., said data from a pivotal study testing Cycloset (bromocriptine mesylate) tablets in patients with poorly controlled Type II diabetes were published in Endocrine Practice

Adventrx Pharmaceuticals Inc., of San Diego, named Brandi L. Roberts chief financial officer and senior vice president...Ambrx Inc., of San Diego, named Lawson Macartney president and CEO

The proceeds from the facility, which follows the receipt in November of a $10 million milestone payment from Santarus Inc., of San Diego, related to the positive readout of the pivotal U.S. Phase III study of Ruconest (conestat alfa), will further strengthen the balance sheet and is foreseen to secure Pharming's cash runway throughout the upcoming regulatory approval process in the U.S

Momenta sued the three companies in September for patent infringement after the FDA approved Amphastar's abbreviated new drug application for another follow-on 1/30/12 Amylin Pharmaceuticals Inc. (San Diego) Carl Icahn and his affiliates Amylin no longer faces a lawsuit from Carl Icahn, who voluntarily dismissed the suit, which had sought an extension of the deadline to nominate directors at the 2012 annual meeting